MED
Medifast, Inc.
NYSE · Consumer Cyclical · Personal Products & Services · US
$12.63
+0.72%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 316.9M | 385.8M | 602.5M | 1.1B | 1.6B |
| Cost of Revenue | 97.5M | 110.6M | 157.8M | 296.2M | 458.2M |
| Gross Profit | 219.5M | 275.2M | 444.6M | 775.9M | 1.1B |
| Operating Expenses | |||||
| R&D Expense | 1.1M | — | — | — | — |
| SG&A Expense | 239.0M | 289.4M | 441.7M | 649.4M | 955.6M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (3.3M) | — | — | — | — |
| Total Operating Expenses | 236.8M | 289.4M | 441.7M | 649.4M | 955.6M |
| Cost and Expenses | 334.2M | 400.0M | 599.6M | 945.7M | 1.4B |
| Operating Income (EBIT) | (17.3M) | (14.2M) | 2.9M | 126.4M | 184.8M |
| Non-Operating | |||||
| Interest Income | 5.6M | 5.5M | 4.8M | 2.5M | — |
| Interest Expense | — | — | — | — | 701.0K |
| Net Interest Income | 5.6M | 5.5M | 4.8M | 2.5M | (701.0K) |
| Other Non-Op Income/Expense | 3.3M | 8.6M | 909.0K | 2.4M | (747.0K) |
| Non-Operating Income (excl Interest) | (3.3M) | (8.6M) | (909.0K) | (2.4M) | 46.0K |
| EBT (Pre-Tax Income) | (14.0M) | (5.6M) | 3.8M | 128.8M | 184.1M |
| Income Tax Expense | 11.6M | 13.0M | 1.7M | 29.4M | 40.5M |
| Bottom Line | |||||
| Net Income | (25.6M) | (18.7M) | 2.1M | 99.4M | 143.6M |
| Earnings from Cont. Ops | (25.6M) | (18.7M) | 2.1M | 99.4M | 143.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (25.6M) | (18.7M) | 2.1M | 99.4M | 143.6M |
| Per Share | |||||
| Basic EPS | ($2.33) | ($1.70) | $0.19 | $9.10 | $12.82 |
| Diluted EPS | ($2.33) | ($1.70) | $0.19 | $9.10 | $12.73 |
| Revenue Per Share | $28.46 | $35.13 | $55.12 | $98.50 | $142.79 |
| Shares | |||||
| Basic Shares Outstanding | 11.1M | 11.0M | 10.9M | 10.9M | 11.2M |
| Diluted Shares Outstanding | 11.1M | 11.0M | 11.0M | 10.9M | 11.3M |
| Profitability Metrics | |||||
| EBITDA | (3.6M) | 4.9M | 16.5M | 141.9M | 195.7M |
| D&A | 10.4M | 10.5M | 12.7M | 13.1M | 11.0M |
| EBIT | (14.0M) | (5.6M) | 3.8M | 128.8M | 184.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026